Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance

13Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The Adult/Adolescent Vaccination Report Card (VRC) was developed and validated by Merck in 1998 for use in vaccine clinical trials to collect information from trial subjects on complaints for both local and systemic events after vaccination. This short report describes the revision to the original validated VRC in order to align with the guidelines outlined in the 2007 FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Since the VRC elicits trial subjects' self-reports of any adverse experiences (AE) occurring post vaccination, it was important that subsequent modifications of the VRC retained the original user-friendly characteristics while gathering the appropriate information to closely correspond with the FDA Guidance. A convenience sample of 15 participants (71% females, 87% white and mean (SD) age 45 (13 years) was recruited to obtain feedback in order to revise the Adult/Adolescent VRC. Based on the feedback received, the following were slightly revised: ruler for the measurements of local systemic reactions, severity ratings, and general instructions. The revised VRC is currently being used in Merck vaccine clinical trials. © 2012 Landes Bioscience.

References Powered by Scopus

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults

221Citations
N/AReaders
Get full text

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old

168Citations
N/AReaders
Get full text

Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older

106Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

76Citations
N/AReaders
Get full text

Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination

18Citations
N/AReaders
Get full text

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)

17Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Norquist, J. M., Khawaja, S. S., Kurian, C., Mast, T. C., Liaw, K. L., Robertson, M. N., … Saddier, P. (2012). Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance. Human Vaccines and Immunotherapeutics, 8(9), 1208–1212. https://doi.org/10.4161/hv.21408

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘23‘24010203040

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 24

57%

Researcher 14

33%

Lecturer / Post doc 3

7%

Professor / Associate Prof. 1

2%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 14

40%

Biochemistry, Genetics and Molecular Bi... 12

34%

Medicine and Dentistry 5

14%

Pharmacology, Toxicology and Pharmaceut... 4

11%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 12

Save time finding and organizing research with Mendeley

Sign up for free
0